# Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

> **NCT05904093** · PHASE1 · RECRUITING · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 25 (estimated)

## Conditions studied

- Sickle Cell Disease
- Hb-SS Disease
- Hemoglobin S
- Disease Sickle Cell Anemia
- Sickle Cell Disorders
- Hemoglobin Beta Thalassemia Disease

## Interventions

- **DRUG:** Fostamatinib

## Key facts

- **NCT ID:** NCT05904093
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-18
- **Primary completion:** 2026-05-14
- **Final completion:** 2026-05-14
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05904093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05904093, "Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05904093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*